Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Garrit Jentsch"'
Autor:
Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H. Prins, John Lettieri, David Mitchell, Funan Huang, Marcia S. Brose, Martin Schlumberger, Gerold Meinhardt, Carol E. A. Peña, Bart A. Ploeger
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the inci
Externí odkaz:
https://doaj.org/article/f459c9a764c849519f2e779c790d916b
Autor:
Ofer Feinerman, Garrit Jentsch, Karen E Tkach, Jesse W Coward, Matthew M Hathorn, Michael W Sneddon, Thierry Emonet, Kendall A Smith, Grégoire Altan‐Bonnet
Publikováno v:
Molecular Systems Biology, Vol 6, Iss 1, Pp n/a-n/a (2010)
Understanding how the immune system decides between tolerance and activation by antigens requires addressing cytokine regulation as a highly dynamic process. We quantified the dynamics of interleukin‐2 (IL‐2) signaling in a population of T cells
Externí odkaz:
https://doaj.org/article/662b3f76a4324301a3cabe5e7129ddcd
Autor:
Jonathan L. Kaufman, Robert Z. Orlowski, Andras Strassz, Andreas Pahl, Thorsten Michaels, Anette Last, Hajnalka Szaboki, Garrit Jentsch, Oliver Schoenborn-Kellenberger, Marc-Steffen Raab
Publikováno v:
Blood. 140:7235-7236
Autor:
Helen R. Moreira, Sonja Krösser, Garrit Jentsch, Philipp Steven, David Wirta, Joseph B. Ciolino, John D. Lonsdale, Michael Beckert, George W Ousler, Gail Torkildsen
Publikováno v:
Ophthalmology
Purpose: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (
Autor:
John Lettieri, Funan Huang, Rupert P. Austin, Martin Schlumberger, Marcia S. Brose, Nicolaas H. Prins, Carol Peña, Gerold Meinhardt, David Mitchell, Garrit Jentsch, Bart Ploeger, Joachim Grevel
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the inci
Autor:
Karen E Tkach, Thierry Emonet, Jesse Coward, Kendall A. Smith, Michael W. Sneddon, Garrit Jentsch, Grégoire Altan-Bonnet, Ofer Feinerman, Matthew M Hathorn
Publikováno v:
Molecular Systems Biology
The sensitivity of T cells to interleukin-2 (IL-2) can vary by three orders of magnitude and is determined by the surface densities of the IL-2 receptor α subunits. Regulatory T cells inflict a double hit on effector T cells by lowering the bulk IL-